Trainings and Resources
14 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/14/2023
The next National Prescription Drug Take Back Day is on April 22, 2023. If you have unused or expired prescription medications, you can locate a safe and convenient disposal drop off location using the U.S Drug Enforcement Association's (DEA) website. The DEA aims to help the public remove unneeded medications from their homes as a measure of preventing medication misuse and opioid addiction from ever starting.
Posted 4/14/2021 (updated 9/14/2022)
The Economic Research Service (ERS) at the U.S. Department of Agriculture details their research into contributing factors for geographic differences, with a focus on the widespread introduction of prescription drugs in rural and urban areas. See the Events section below to register for an ERS webinar on this report, taking place at 1:00 pm ET today.
Posted 6/9/2021 (updated 8/24/2022)
Since the beginning of the COVID-19 pandemic, its consequences have had a severe effect on mental health (Czeisler et al., 2020; Sher, 2020). Factors such as economic anxiety, social isolation due to necessary social distancing regulations, anxiety and fear regarding the virus, and chronic stress are factors that have contributed to the increase in mental health symptoms (Sher, 2020). Since the start of the pandemic, there have been notable increases in depression and anxiety and increased psychological distress in both the general population and among healthcare professionals (Sher, 2020). A large survey of adults in the U.S. found that there was a substantial increase in anxiety and depressive symptoms endorsed compared to the same time the previous year (Czeisler et al., 2020).
Posted 3/22/2022 (updated 8/17/2022)
Yesterday, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), is announcing two grant programs totaling $25.6 million that will expand access to medication-assisted treatment for opioid use disorder and prevent the misuse of prescription drugs. By reducing barriers to accessing the most effective, evidenced-based treatments, this funding reflects the priorities of HHS' Overdose Prevention Strategy, as well as its new initiative to strengthen the nation's mental health and crisis care systems.
Posted 3/24/2022 (updated 8/17/2022)
If you received specific disposal instructions from your healthcare provider (e.g., doctor, pharmacist) for your unused or expired medicine, you should follow those instructions to dispose of your medicine. The best disposal option is to find a drug take back location, which may be found in retail, hospital, or clinic pharmacies; and/or law enforcement facilities.
Posted 4/20/2022 (updated 5/6/2022)
This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Posted 3/15/2022
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 8/11/2021 (updated 9/2/2021)
The Office of the Assistant Secretary for Planning and Evaluation (ASPE) contracted with
RTI International to conduct a scoping review of the scientific literature on non-fatal opioidinvolved overdose (NFOO) to better understand the health outcomes and health care implications
associated with opioid epidemic. NFOO is a significant cause of opioid-related morbidity in the
United States, and is of heightened interest to ASPE given the sharp increase in fatal and nonfatal opioid overdoses as a result of the current fentanyl crisis. Compared to the first and second
phases of the opioid epidemic, when the majority of opioid-related morbidity and mortality was
associated first with prescription opioids and then with heroin, illicitly-manufactured fentanyl
(IMF) is now the leading cause of fatal opioid overdoses (CDC, 2017; O’Donnell, Gladden, &
Seth, 2017). People who consume IMF, either wittingly or unwittingly, are at higher risk for
accidental overdose, experience comparatively atypical overdose-related side effects, have
unique risk profiles, and are at higher risk for poorer health outcomes (Somerville, 2017). To our
knowledge, no investigation has been conducted to examine whether the sharp increase in
NFOOs over the last several decades is negatively impacting overdose victims’ chronic physical
and mental health outcomes. To investigate the status of the scientific literature regarding the
consequences of NFOO on victims’ physical and mental health, we conducted a scoping review
of the existing knowledge in multiple stages: (1) publication identification; (2) selection of
publications; and (3) data extraction, charting, and synthesis. Key findings from our review are
presented below.
Posted 4/21/2021 (updated 9/2/2021)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/7/2021 (updated 9/2/2021)
The U.S. Government Accountability Office (GAO) recently published their Drug Misuse report to the Congressional Committees, which stemmed from a provision in the Comprehensive Addiction and Recovery Act of 2016 (CARA) requiring GAO to review Good Samaritan and Naloxone Access Laws. GAO examined which states and territories have Good Samaritan and Naloxone Access laws, the effects of Good Samaritan laws, and the efforts the Office of National Drug Control Policy (ONDCP) has taken to disseminate information on Good Samaritan and Naloxone Access laws. GAO found that 47 states and D.C. have enacted both Good Samaritan and Naloxone Access laws, Kansas, Texas and Wyoming only have Naloxone Access laws, and five U.S. territories do not have any Good Samaritan or Naloxone Access laws in place. They also conducted literature reviews of studies examining the laws’ effectiveness and ONCDP documents and found that, while there were lower rates of overdose deaths in states with Good Samaritan laws, awareness of Good Samaritan laws varied across states and territories.